SANTA MONICA, Calif.--(BUSINESS WIRE)--
Kite Pharma, Inc., (Nasdaq:KITE), a leading cell therapy company, has
been named to MIT Technology Review's 2017 list of 50 Smartest
Companies. To make the list, a company must exhibit technological
leadership and business acumen which sets them apart from competitors.
Kite was ranked #7 on this list for its leadership in establishing the
field of engineered cell therapy for the treatment of cancer.
"The companies on the list combine a high level of technology innovation
with a business model that will help them make the most of it," said
Nanette Byrnes, senior editor for business of MIT Technology Review.
"Public and private, large and small, based in countries around the
globe, this group of companies is creating new opportunities and
pouncing on them. These are the ones that competitors must follow."
The decades long journey of developing chimeric antigen receptor (CAR)
technology by institutions such as the National Cancer Institute has
seen tremendous advancement in just the last few years. Beginning in
late 2014, Kite was able to accelerate development of engineered cell
therapy and its lead CAR-T candidate, axicabtagene ciloleucel. That
effort led to the presentation earlier this year of positive data from
ZUMA-1, the first pivotal CAR-T trial in patients with refractory
aggressive B-cell non-Hodgkin lymphoma (NHL). A Biological License
Application (BLA) for axicabtagene ciloleucel has been accepted by the
FDA and, if approved, Kite plans to commercially launch axicabtagene
ciloleucel in 2017.
"Kite is honored to be included and recognized as part of MIT Technology
Review's 50 Smartest Companies List for our work in establishing CAR-T
therapy," said Arie Belldegrun, MD, FACS, Chairman, President and Chief
Executive Officer of Kite. "This year will be a transformative year
across the industry for this paradigm-changing technology, which
includes the potential approval by the FDA of axicabtagene ciloleucel.
At Kite, we utilized the years of pioneering research from our academic
collaborators and assembled a team of industry experts to advance
engineered cell therapies from early research to full commercialization
to address an important unmet clinical need."
The list is included in MIT Technology Review's annual business issue,
which is available online
now and on newsstands worldwide on July 4, 2017.
About MIT Technology Review
Founded at the Massachusetts Institute of Technology in 1899, MIT
Technology Review is a digitally oriented independent media company
whose analysis, features, reviews, interviews, and live events explain
the commercial, social, and political impact of new technologies. MIT
Technology Review readers are curious technology enthusiasts—a global
audience of business and thought leaders, innovators and early adopters,
entrepreneurs and investors. Every day, MIT Technology Review provides
an authoritative filter for the flood of information about technology.
The company is the first to report on a broad range of new technologies,
informing its audiences about how important breakthroughs will impact
their careers and their lives. Subscribe. Follow MIT Technology Review: Twitter,
Kite is a biopharmaceutical company engaged in the development of
innovative cancer immunotherapies with a goal of providing rapid,
long-term durable response and eliminating the burden of chronic care.
The company is focused on chimeric antigen receptor (CAR) and T cell
receptor (TCR) engineered cell therapies designed to empower the immune
system's ability to recognize and kill tumors. Kite is based in Santa
Monica, CA. For more information on Kite, please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the timing and
ability of obtaining regulatory approval and commercially launching
axicabtagene ciloleucel and the ability to advance engineered cell
therapies. Various factors may cause differences between Kite's
expectations and actual results as discussed in greater detail in Kite's
filings with the Securities and Exchange Commission, including without
limitation in its Form 10-Q for the quarter ended March 31, 2017. Any
forward-looking statements that are made in this press release speak
only as of the date of this press release. Kite assumes no obligation to
update the forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this press
View source version on businesswire.com: http://www.businesswire.com/news/home/20170627005518/en/
SVP, Corporate Communications &
VP, Investor Relations
Source: Kite Pharma, Inc.
News Provided by Acquire Media